The Filing Desk

PROCEPT BioRobotics vs STAAR Surgical

PROCEPT BioRobotics PRCT · STAAR Surgical STAA · Health Care Equipment

PROCEPT BioRobotics reported revenue of $308 million in fiscal 2025, 1.3 times STAAR Surgical's $239 million in fiscal 2025. PROCEPT BioRobotics' revenue grew 37.2% in its latest year, and STAAR Surgical's fell 23.7%. PROCEPT BioRobotics had an operating margin of -33.7%, against -38.3% at STAAR Surgical. Free cash flow was −$58 million at PROCEPT BioRobotics and −$40 million at STAAR Surgical. Their fiscal years end in different months (December 31 and January 2), so the periods don't line up exactly.

Side by side

PROCEPT BioRoboticsSTAAR Surgical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Jan 2, 2026
Revenue$308M$239M
Revenue growth37.2%−23.7%
Revenue growth a year, last 5 years109.1%7.9%
Gross margin63.7%76.2%
Operating margin−33.7%−38.3%
Net margin−31.0%−33.6%
Free cash flow−$58M−$40M
Free cash flow margin−18.9%−16.7%
Return on capital−65.4%—
Net debt to EBITDA——
Dividends and buybacks$0M$6M
Change in diluted share count6.6%0.9%
Last close$23.80$26.39
P/E at the last close——
Insider trades, last 12 months—bought $62.8 million, sold $0
Piotroski F-score5 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
PROCEPT BioRoboticsSTAAR Surgical
Operating margin
Percent of revenue
PROCEPT BioRoboticsSTAAR Surgical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PROCEPT BioRoboticsSTAAR Surgical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the PROCEPT BioRobotics and STAAR Surgical pages.